October 03, 2023
Zymergen Inc.
Case Number:
1:23-bk-11661
Court:
Nature of Suit:
Firms
- Buchalter APC
- Chipman Brown
- Connolly Gallagher
- Cross & Simon
- Faegre Drinker
- Felderstein Fitzgerald
- Goodwin Procter
- Landis Rath
- Lowenstein Sandler
- Margolis Edelstein
- Mayer Brown
- Monzack Mersky
- Morgan Lewis
- Morris Nichols
- Pachulski Stang
- Porzio Bromberg
- Potter Anderson
- Robbins Geller
- Saul Ewing
- Simpson Thacher & Bartlett LLP
- Sullivan & Cromwell
- Wilson Sonsini
- Young Conaway
Companies
- ASM Capital LP
- Chilmark Partners LLC
- Fortis Advisors LLC
- Intrepid Investment Bankers
- JPMorgan Chase & Co.
- Lazard Ltd.
- Lighthouse eDiscovery Inc.
- Oracle Corp.
- Pivot Bio Inc.
- The Cigna Group
- The Goldman Sachs Group Inc.
- UBS Group AG
- Zymergen Inc.
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
February 05, 2024
Zymergen Ch. 11 Plan Confirmed After Investor Objection
Biotechnology company Zymergen received confirmation of its Chapter 11 plan Monday at a hearing in Delaware bankruptcy court after resolving an objection to the plan from a class of investors suing the company.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
View the parties now
Already a subscriber? Click here to login